Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitorsJakob M. Riedl, Ryan B. Corcoran, Ferran Fece de la Cruz et al.|Annals of Oncology|2025Cited by 49
TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerRachel O. Abelman, Aditya Bardia, Elena Bitman et al.|Clinical Cancer Research|2025Cited by 39
Abstract 3888: <i>TOP1</i> mutations mediate cross resistance to ADCs in metastatic breast cancerRachel O. Abelman, Aditya Bardia, Haley Barnes et al.|Cancer Research|2024Cited by 2